MOLN
Molecular Partners AG
NASDAQ · Healthcare · Biotechnology · CH
$4.11
−5.52%Year over year
Reported trailing growth
- Revenue
- -100.0%
- EBITDA
- +12.9%
- EBIT
- +10.7%
- EPS
- +25.8%
- Free cash flow
- +10.1%
- Operating cash flow
- +9.1%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- -1.6%
Three-year CAGR
- Revenue
- -100.0%
- EBITDA
- -15.2%
- EBIT
- +5.1%
- Net income
- -14.1%
- EPS
- -3.8%
- Free cash flow
- +13.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026